GNAS and pancreatic intraductal papillary-mucinous neoplasm: The detection of GNAS mutations in cfDNA before the emergence of a visible IPMN highlights the potential of liquid-biopsy to help in the risk stratification of patients undergoing pancreatic screening and surveillance.